Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that ... Franklin Credit Management Corporation, 2 days ago
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O'Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO - FierceBiotech, 1 week ago
More from: CNBC, Stock Nod...and 36 other sources
Physician-Reported Patient Share for Regeneron's Eylea Has Now Stabilized Following Significant Increases after Its U.S. Launch for Wet Age-Related Macular Degeneration
BURLINGTON, Mass. , Aug. 14, 2014 /PRNewswire/ --Decision Resources Group finds that physician-reported patient shares for Regeneron's Eylea, as well as the other major anti-vascular endothelial growth factor (VEGF) agents Genentech/Roche's Avastin ...CEOWorld Magazine, 1 month ago
More from: Town Hall, Town Hall...and 21 other sources
on your WebpageAdd Widget >Get your members hooked!